We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.11, moving +1.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.11%. At the same time, the Dow lost 0.13%, and the tech-heavy Nasdaq gained 0.18%.
Coming into today, shares of the biotechnology company had lost 15.93% in the past month. In that same time, the Medical sector lost 6.43%, while the S&P 500 lost 4.28%.
Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.27, showcasing a 46% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $20.73 million, indicating a 40.65% growth compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.93 per share and revenue of $90.52 million, indicating changes of +35.42% and +21.21%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Recursion Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 145, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.11, moving +1.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.11%. At the same time, the Dow lost 0.13%, and the tech-heavy Nasdaq gained 0.18%.
Coming into today, shares of the biotechnology company had lost 15.93% in the past month. In that same time, the Medical sector lost 6.43%, while the S&P 500 lost 4.28%.
Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.27, showcasing a 46% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $20.73 million, indicating a 40.65% growth compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.93 per share and revenue of $90.52 million, indicating changes of +35.42% and +21.21%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Recursion Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 145, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.